Volume 61, Issue 2, Pages (February 2002)

Slides:

Advertisements

Similar presentations

V.M. Campese, N. Mitra, D. Sandee Kidney International

Advertisements

Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction

Viper venom for diabetic nephropathy

Thinking Beyond New Clinical Guidelines: Update in Hypertension

Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation Anil K. Bidani, M.D., Karen A. Griffin,

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Rajiv Agarwal, John W. Kusek, Maria K. Pappas Kidney International

Membranous nephropathy: When and how to treat

Viper venom for diabetic nephropathy

Volume 64, Issue 2, Pages (August 2003)

Volume 58, Issue 6, Pages (December 2000)

Renoprotective effects of vitamin D analogs

Propofol as a panacea for acute kidney injury?

Volume 81, Issue 7, Pages (April 2012)

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

The intrarenal renin-angiotensin system in hypertension

Response to is the reduction in urea distribution volume over time in clinically stable dialysis patients real? S. Andrulli, S. Di Filippo, F. Locatelli

Volume 63, Issue 3, Pages (March 2003)

Volume 80, Issue 9, Pages (November 2011)

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy S.C.W. Tang, J.C.K.

V.M. Campese, N. Mitra, D. Sandee Kidney International

Volume 57, Pages S32-S37 (April 2000)

Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency Fiona E. Mackie, Timothy W. Meyer,

A new era in phosphate binder therapy: What are the options?

Volume 82, Issue 3, Pages (August 2012)

Volume 72, Issue 12, Pages (December 2007)

Renal risk scores: Progress and prospects

Volume 87, Issue 2, Pages (February 2015)

Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension A. Davenport, C. Cox, R. Thuraisingham Kidney.

Volume 74, Issue 8, Pages (October 2008)

Volume 63, Issue 6, Pages (June 2003)

Elke Wühl, Otto Mehls, Franz Schaefer Kidney International

Volume 65, Issue 6, Pages (June 2004)

Volume 69, Issue 12, Pages (June 2006)

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

Special deLIVERy: podocyte injury promotes renal angiotensin II generation from liver- derived angiotensinogen David I. Ortiz-Melo, Robert F. Spurney

Angiotensin-(1–7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells Z. Su, J. Zimpelmann, K.D. Burns Kidney.

Volume 67, Issue 1, Pages (January 2005)

Volume 53, Issue 4, Pages (April 1998)

Extracorporeal therapy in sepsis: are we there yet?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

The future of renoprotection: Frustration and promises

Volume 78, Issue 1, Pages (July 2010)

Volume 84, Issue 5, Pages (November 2013)

The kidney, a cardiovascular risk marker, and a new target for therapy

Volume 67, Pages S52-S54 (January 2005)

Volume 63, Issue 2, Pages (February 2003)

Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter? Dimitris Mavridis, PhD American Journal.

Volume 66, Pages S18-S21 (November 2004)

The treatment of acute interstitial nephritis: More data at last

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

Carmine Zoccali, Francesca Mallamaci Kidney International

Volume 73, Issue 5, Pages (March 2008)

Volume 53, Issue 6, Pages (June 1998)

Changbin Qiu, Chris Baylis Kidney International

Volume 68, Issue 5, Pages (November 2005)

Volume 60, Issue 3, Pages (September 2001)

Is it the low-protein diet or simply the salt restriction?

Volume 64, Issue 4, Pages (October 2003)

Volume 67, Issue 5, Pages (May 2005)

Volume 66, Pages S7-S10 (November 2004)

Inhibition of the renin–angiotensin system: is more better?

Volume 74, Issue 9, Pages (November 2008)

Sandrine Billet, Fréderick Aguilar, Camille Baudry, Eric Clauser

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications

Proteinuria and hypertension with tyrosine kinase inhibitors

Antonio Piccoli, Luana Pillon Kidney International

Presentation transcript:

Volume 61, Issue 2, Pages 473-480 (February 2002) Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis Hendrik Bos, Robert H. Henning, Eric De Boer, Anton T.M.G. Tiebosch, Paul E. De Jong, Dick De Zeeuw, Gerjan Navis Kidney International Volume 61, Issue 2, Pages 473-480 (February 2002) DOI: 10.1046/j.1523-1755.2002.00154.x Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 1 Scheme of the study. Induction of nephrosis at week 0. Stratification at week 6 according to baseline proteinuria. Forty-five rats were treated by lisinopril 75 mg/L during two weeks. These rats were re-stratified at week 8 according to residual proteinuria. AII-A is angiotensin II inhibitor. Kidney International 2002 61, 473-480DOI: (10.1046/j.1523-1755.2002.00154.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 2 Correlation of the antiproteinuric response to initial treatment with monotherapy lisinopril at week 8 and to subsequent co-treatment with angiotensin II subtype 1 receptor antagonist (AII-A) at week 12. The line of identity is shown. Kidney International 2002 61, 473-480DOI: (10.1046/j.1523-1755.2002.00154.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 3 Proteinuria (median and 95% CI) at onset of treatment (week 6; stratification), after two weeks of monotherapy lisinopril (week 8, re-stratification) and at week 12 (end of study) according to final treatment regimen. Data are given for the whole group, and according to a break-up for good and poor response to the initial two weeks of angiotensin-converting enzyme (ACE) inhibition. Kidney International 2002 61, 473-480DOI: (10.1046/j.1523-1755.2002.00154.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 4 Correlation between residual proteinuria at week 12, that is, at the end of the study, and the focal glomerulosclerosis score (FGS score, left Y-axes, •) as well as the interstitial injury score (right Y-axes, ○) in all groups on active treatment. For clarity, only the regression line and correlation coefficient of the correlation between residual proteinuria and FGS score are shown. Kidney International 2002 61, 473-480DOI: (10.1046/j.1523-1755.2002.00154.x) Copyright © 2002 International Society of Nephrology Terms and Conditions